Research Topics
Species | Angela H BrodieSummaryAffiliation: University of Maryland Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cellsTesfom Abrhale
A and G Pharmaceutical Inc, 9130 Red Branch Rd, Columbia, MD, USA
BMC Cancer 11:231. 2011..In the present study, we investigated the role GP88 on the acquisition of resistance to letrozole in ER+ breast cancer cells..- Aromatase and breast cancerA Brodie
Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, MD 21201, USA
J Steroid Biochem Mol Biol 102:97-102. 2006..These results suggest that blocking both ER- and growth factor-mediated transcription may delay development of resistance and maintain growth inhibition of ER+ breast cancer... - David Kupfer and the metabolism connection: on aromatase inhibitors and tamoxifenAngela Brodie
Department of Pharmacology and Experimental Therapeutics, University of Maryland, School of Medicine, USA
Drug Metab Rev 38:129-37. 2006..This tribute to Dr. David Kupfer describes his contributions to understanding the actions and interactions of tamoxifen and aromatase inhibitors through their metabolites and their role in breast cancer treatment and prevention... - Model systems: mechanisms involved in the loss of sensitivity to letrozoleAngela Brodie
Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Health Science Facilities 1, Room 580, 685 West Baltimore Street, Baltimore, MD 21201, USA
J Steroid Biochem Mol Biol 95:41-8. 2005..The results suggest that achieving more complete estrogen blockade may delay development of hormone-independent signaling pathways regulating proliferation... - Therapeutic observations in MCF-7 aromatase xenograftsAngela Brodie
Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland, USA
Clin Cancer Res 11:884s-8s. 2005..Thus, achieving more complete estrogen blockade may delay development of hormone-independent signaling pathways regulating proliferation... - The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancerAngela Brodie
Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Urol Oncol 27:53-63. 2009..To improve treatment for patients with breast and prostate cancer... - The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogensAngela H Brodie
Department of Pharmacology and Experimental Therapeutics, School of Medicine, University of Maryland, 655 W Baltimore Street, Baltimore, MD 21201, USA
J Steroid Biochem Mol Biol 86:283-8. 2003..This suggests that resistance to letrozole may be reversible, allowing tumors to respond to subsequent antiestrogens and letrozole... - Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogensAngela Brodie
Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21202 1559, USA
Clin Cancer Res 9:455S-9S. 2003..These results demonstrate that this aromatase inhibitor is more effective and has a longer duration of response as a single agent than tamoxifen or in combination with tamoxifen... - Aromatase inhibition and inactivationA Brodie
Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore 21202, USA
Clin Cancer Res 7:4343s-4349s; discussion 4411s-4412s. 2001..We have developed a unique animal model with human tumors to compare the antitumor efficacy of antiestrogens and aromatase inhibitors and to optimize their use in sequence and combination as a guide for future clinical trials... - Aromatase inhibitors in breast cancerAngela Brodie
Department Pharmacology and Experimental Therapeutics, School of Medicine, University of Maryland, Baltimore, MD 21201, USA
Trends Endocrinol Metab 13:61-5. 2002..Because two types of aromatase inhibitors are available, steroidal enzyme inactivators and reversible non-steroidal inhibitors in sequential therapy could be useful if resistance to one type develops... - Aromatase and COX-2 expression in human breast cancersA M Brodie
Department of Pharmacology, School of Medicine, University of Maryland, Room 580 G, Baltimore, MD 21201, USA
J Steroid Biochem Mol Biol 79:41-7. 2001..In addition, the duration of response was significantly longer with the aromatase inhibitor than with tamoxifen, suggesting that aromatase inhibitors may offer better control of tumor growth than this antiestrogen... - Aromatase resistance mechanisms in model systems in vivoAngela Brodie
Department of Pharmacology and Experimental Therapeutics, School of Medicine, University of Maryland Baltimore, Baltimore, MD 21201, USA
J Steroid Biochem Mol Biol 118:283-7. 2010..These and other strategies to restore aromatase and ERalpha resulting in sensitivity to hormone therapy could be of substantial benefit to patients who have acquired resistance to AIs... - Aromatase inhibitors and their application in breast cancer treatment*A M Brodie
Department of Pharmacology, School of Medicine, University of Maryland, 685 West Baltimore Street, Baltimore, MD, USA
Steroids 65:171-9. 2000..Although studies of the efficacy of these agents in earlier stage disease are awaited, it is evident that aromatase inhibitors can extend the duration of treatment in breast cancer patients... - Aromatase and its inhibitorsA Brodie
Department of Pharmacology and Experimental Therapeutics, School of Medicine, University of Maryland, Baltimore 21201, USA
J Steroid Biochem Mol Biol 69:205-10. 1999..This suggests that sequential treatment with these agents is likely to be more beneficial to the patient in terms of longer response to treatment... - Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitorsAngela Brodie
Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland, USA
Clin Cancer Res 17:4208-13. 2011..Functional activation of the mitogen-activated protein kinase pathway and dependency on growth factor receptor signaling have been observed in AI-resistant cells and tumors... - Xenograft models for aromatase inhibitor studiesA Brodie
Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, The Greenebaum Cancer Center, Baltimore, MD 21201, USA
J Steroid Biochem Mol Biol 106:119-24. 2007..These results suggest that blocking both ER and growth factor mediated transcription may delay development of resistance to letrozole and maintain its growth inhibition of breast cancer... - Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapyAngela H Brodie
Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland, USA
Am J Clin Oncol 26:S17-26. 2003..This model is now being used to assess whether combined or sequential administration of AIs with other agents may provide additional benefit... - A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase geneW Yue
Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore 21201
Cancer Res 54:5092-5. 1994..Thus, it simulates the situation in the postmenopausal breast cancer patient and could be used to evaluate the effect of aromatase inhibitors and antiestrogens... - Aromatase expression in the human maleA Brodie
Department of Pharmacology and Experimental Therapeutics, University of Maryland, School of Medicine, Baltimore, MD 21201, USA
Mol Cell Endocrinol 178:23-8. 2001..Several members of the patient's family including his sister also expressed high levels of aromatase. This condition appears to be inherited in an autosomal dominant manner... - Intrauterine growth retardation associated with precocious puberty and sertoli cell hyperplasiaM B Lodish
Section on Endocrinology Genetics, Program on Developmental Endocrinology Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, and Pediatric Endocrinology Inter Institute Training Program, National Institutes of Health, Bethesda, MD, USA
Horm Metab Res 42:682-8. 2010..We conclude that in a patient with a Russell-Silver syndrome-like phenotype, Sertoli cell hyperplasia was associated with somatic trisomy 8, increased aromatization, and gonadotropin-independent precocious puberty... - Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compoundsI P Nnane
Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore 21201, USA
Endocrinology 140:2891-7. 1999..Although future improvements in their bioavailability are necessary, these novel steroidal compounds show promise as potential agents for reducing T and DHT levels in patients with androgen dependent diseases... - Challenges in the endocrine management of breast cancerHenning T Mouridsen
Department of Oncology, Rigshospitalet, Copenhagen, Denmark
Breast 12:S2-19. 2003..These assessments also clearly indicated the eagerness of patients to participate actively in treatment decisions..
Research Grants
- AROMATASE AND BREAST CANCERAngela M Brodie; Fiscal Year: 2010..These strategies will be tested in our unique model to determine their anti-tumor efficacy. The results of these studies could improve treatment for breast cancer patients. ..
- AROMATASE AND BREAST CANCERAngela Brodie; Fiscal Year: 2002..abstract_text> ..
- AROMATASE AND BREAST CANCERAngela M Brodie; Fiscal Year: 2010..These strategies will be tested in our unique model to determine their anti-tumor efficacy. The results of these studies could improve treatment for breast cancer patients. ..
- AROMATASE AND BREAST CANCERAngela Brodie; Fiscal Year: 2009..These strategies will be tested in our unique model to determine their anti-tumor efficacy. The results of these studies could improve treatment for breast cancer patients. ..
- ANDROGEN SYNTHESIS INHIBITORS FOR PROSTATE CANCERAngela Brodie; Fiscal Year: 2007..Determine effective doses, scheduling, and route of administration and b. Compare the effect of lead inhibitors and castration on apoptosis to identify the best compound. ..
- AROMATASE AND BREAST CANCERAngela Brodie; Fiscal Year: 2007..In the fourth Specific Aim, we will determine whether HER2 and MAPKinase inhibitors are effective in preventing the development of or overcoming resistance to letrozole in the xenograft model. ..
- ANDROGEN SYNTHESIS INHIBITORS FOR PROSTATE CANCERAngela Brodie; Fiscal Year: 2003..These studies should enable us to select the most effective inhibitors by the end of the grant period, that can then be advanced to phase I trials. ..
- AROMATASE INHIBITORS FOR CONTROL OF BREAST CANCERAngela Brodie; Fiscal Year: 1980..We also propose to apply aromatase inhibitors to studying the interrelationships of estrogen with other hormones and their effects on steroid hormone plasma and receptor levels. ..
- AROMATASE INHIBITORS, BREAST CANCER, AND OTHER DISEASESAngela Brodie; Fiscal Year: 1991..Similar in vitro studies to the above will be carried out in tissue from patients with benign prostatic hypertrophy and prostatic cancer. Prostatic tissues will also be grown in nude mice and the effect of 4-OHA on the tumors determined...
- AROMATASE AND ANDROGEN INHIBITORS IN PROSTATE CANCERAngela Brodie; Fiscal Year: 1993..Effective inhibitors of androgen and estrogen biosynthesis could be of value in the treatment of prostate cancer...